Driven by a desire to help ex-servicemembers with mental illness, GOP lawmakers led a failed campaign last year to persuade the Biden administration to approve psychedelic drugs. Now they may have found the ally they need in President Donald Trump’s health secretary, Robert F. Kennedy Jr. RFK Jr. is bringing psychedelics to the Republican party
CTIS 2025: Automated Assessment Auditing Across MindMed’s Pivotal Programs Presentedy by: Dan Karlin, Chief Medical Officer, MindMed
MAPS supporting MM-120 Trial - Poston Instagram. I would say this is big. https://www.instagram.com/p/DL-eltENqfw/?igsh=bzJscXQ4NzVyMzl1
RFK Jr. and other Trump officials embrace psychedelics after FDA setback https://apnews.com/article/psychede...bogaine-mdma-4e59a3eb2d23d98f2579d25c73c34e9b
$MNMD J&J doesn't have to 'do deals out of desperation' despite facing patent cliffs: CFO https://finance.yahoo.com/news/jj-d...spite-facing-patent-cliffs-cfo-112624430.html "Our portfolio and pipeline position us for elevated growth in the second half of the year, with game-changing approvals and submissions anticipated in areas like lung and bladder cancer, major depressive disorder, psoriasis, surgery, and cardiovascular, which will extend and improve lives in transformative ways," MM-120 for MDD Jay Woods, Freedom Capital Markets' chief global strategist, recently told Yahoo Finance "all eyes are on how J&J and others are going to manage their M&A strategy to account for the significant revenue losses attributed to patent expiries. Wolk told Yahoo Finance the company is looking at a strong balance sheet, with $20 billion on hand, plus capital deployment of $55 billion in the last few years for large to small M&A deals. Of the $55 billion, $10 billion was used on 80 small deals, he said.
List of Patent Activity on 2025 for MindMed US20250205196 – Formulations of Psilocin with Enhanced Stability Jurisdiction: United States Publication Date: June 26, 2025 Patent Link - https://patentscope.wipo.int/search/en/detail.jsf?docId=US458475369&_cid=P22-MD7DGB-14617-2 Summary: Covers novel psilocin formulations with improved chemical stability. Strategic Value: Strengthens MindMed’s ability to commercialize shelf-stable, fast-acting psychedelic therapies in the U.S. EP4551680 – Methods of Manufacture of R-MDMA Jurisdiction: European Patent Office Publication Date: May 14, 2025 Patent Link - https://patentscope.wipo.int/search/en/detail.jsf?docId=EP455657588&_cid=P22-MD7DGB-14617-9 Summary: Describes synthetic methods specifically for the R-enantiomer of MDMA. Strategic Value: Expands MindMed’s IP footprint in Europe and enables proprietary production of next-generation empathogenic compounds. WO2025128594 – Methods of Treating Generalized Anxiety Disorder Jurisdiction: International (WIPO/PCT) Publication Date: June 19, 2025 Patent Link - https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2025128594&_cid=P22-MD7DGB-14617-12 Summary: Claims the use of psychoactive compounds for the treatment of Generalized Anxiety Disorder. Strategic Value: Broadens MindMed’s therapeutic claims globally and supports expansion into anxiety-related indications. US20250019359 – R-MDMA Crystal Forms Jurisdiction: United States Publication Date: January 16, 2025 Patent Link - https://patentscope.wipo.int/search/en/detail.jsf?docId=US446172274&_cid=P22-MD7DGB-14617-3 Summary: Discloses crystalline polymorphs of R-MDMA, which influence drug stability and bioavailability. Strategic Value: Secures commercial control over specific drug forms as MindMed moves toward clinical and market-ready formulations in the U.S. AU2025204612 – MDMA Enantiomers Jurisdiction: Australia Publication Date: July 3, 2025 Patent Link - https://patentscope.wipo.int/search/en/detail.jsf?docId=AU458866182&_cid=P22-MD7DGB-14617-7 Summary: Covers both R- and S-enantiomers of MDMA, including their compositions and uses. Strategic Value: Enhances MindMed’s global IP portfolio and supports international protection of its novel empathogen drug candidates.
PBS - RFK Jr. suggests psychedelic therapy for depression and trauma has Trump administration’s support https://www.pbs.org/newshour/health...for-psychedelic-therapy-for-depression-trauma
